Zacks Investment Research downgraded shares of CARDIOME PHARMA (CRME) from NEUTRAL to UNDERPERFORM on May 21, 2012, with a target price of $0.40.
Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CARDIOME PHARMA (CRME),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment